Parameter Total (n=186)
VA (n=52)
No VA (n=134)
p
Age 66.4±12 66.8±11.8 66.7±11.7 0.7
Gender (Male) 158 (84.9%) 48 (92.3%) 110 (82.1%) 0.08
Heart Rate (admission) 72.5±14 75.7±16 71.4±12 0.068
ICD 79 (42.5%) 26 (50%) 53 (39.6%) 0.22
CRTD 107 (57.5%) 26 (50%) 81 (60.4%) 0.2
Ischemic CM 115 (61.8%) 29 (55.7%) 86 (64.1%) 0.25
HTN 130 (69.8%) 35 (67.3%) 95 (70.8%) 0.7
DM 79 (42.4%) 14 (26.9%) 65 (48.5%) 0.008
Renal dysfunction 66 (35.4%) 17 (32.7%) 49 (36.5%) 0.7
Number of guideline-based medications 2.3±0.75 2.3±0.83 2.25±0.7 0.8
BB treatment 155 (83.3%) 40 (79.6%) 115 (85.8%) 0.14
BB dose (% target) 32±25% 23.9±19% 35.5±27% 0.012
BB > 25% target dose 68 (36.5%) 12 (23%) 56 (41.8%) 0.084
AngA treatment 162 (87.1%) 46 (88.5%) 116 (86.6%) 0.73
AngA dose (% target) 38.2±30% 41.2±32% 37±30% 0.38
AngA > 25% target dose 90 (48.3%) 27 (51.9%) 63 (47%) 0.943
MRA treatment 110 (59.1%) 31 (59.6%) 79 (59%) 0.93
MRA dose (% target) 31±30% 32.2±30.8% 30.4±30% 0.74
MRA > 25% target dose 88 (47.3%) 26 (50%) 62 (46.3%) 0.932
AAD treatment 81 (43.5%) 22 (42.3%) 59 (44%) 0.83
BB+AngA+MRA treatment 86 (46.2%) 21 (40.4%) 65 (48.5%) 0.33
Follow up period (median[IQR], days) 1399 [752,2432] 1819 [930,3140] 1326 [679,2113] 0.005